PTC THERAPEUTICS

Company snapshot

PTC THERAPEUTICS maintains 52 tracked programs across Phenylketonuria, Amyotrophic Lateral Sclerosis, Cystic Fibrosis, Duchenne Muscular Dystrophy, Leigh Syndrome, Metabolic Disorders - Phenylketonuria, Huntington’s Disease, Friedreich ataxia, Aromatic Amino Acid Decarboxylase Deficiency, Amino Acid Metabolism, Inborn Errors, Aniridia, Epilepsy. Momentum score: 20/100 (30-day delta: n/a). Public r

• 2 approved product(s) across US/EU regulatory metadata.
• 52 active pipeline program(s) linked via ClinicalTrials.gov.
• 149 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for PTC THERAPEUTICS. Not investment advice.

• Peer + 0 momentum

  BioMarin Pharmaceutical Australia

  TA overlap score 38.2

• Peer + 0 momentum

  Aquestive Therapeutics

  TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for PTC THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   PTC923-PKU-401 — Phase 3

2. Jun 8, 2026 Clinical update

   PTC923-PKU-301 — Phase 3

3. Jun 8, 2026 Clinical update

   PTC857-CNS-001-ALS — Phase 2

4. Jun 8, 2026 Clinical update

   PTC518-CNS-002-HD — Phase 2

5. Jun 8, 2026 Clinical update

   VEGF inhibitor PTC299 — Phase 2

View all clinical trial activity →

• What is PTC THERAPEUTICS?

  PTC THERAPEUTICS is a pharma organization headquartered in WARREN, NJ, USA. It trades on NYSE under ticker PTCT. Primary therapeutic focus areas include Phenylketonuria, Amyotrophic Lateral Sclerosis, Cystic Fibrosis, Duchenne Muscular Dystrophy, Leigh Syndrome. NovaPharmaNews li

• Is PTC THERAPEUTICS publicly traded?

  Yes. PTC THERAPEUTICS is listed with ticker PTCT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does PTC THERAPEUTICS develop or market?

  We link 21 drug profile(s) where PTC THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ptc-therapeutics-inc#company-drugs.

• What are the latest developments for PTC THERAPEUTICS?

  In the last 12 months our linked public records show 52 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does PTC THERAPEUTICS focus on?

  PTC THERAPEUTICS focuses on Phenylketonuria, Amyotrophic Lateral Sclerosis, Cystic Fibrosis based on our analysis of their pipeline programs and drug development activities.